Recent Advances in CAR-Based Solid Tumor Immunotherapy
Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in the treatment of hematological malignancies. However, their limitations in solid tumors include an immunosu...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-06-01
|
| Series: | Cells |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2073-4409/12/12/1606 |
| _version_ | 1797595625020194816 |
|---|---|
| author | Min Hwa Shin Eunha Oh Yunjeong Kim Dae-Hwan Nam So Young Jeon Jin Hyuk Yu Dohsik Minn |
| author_facet | Min Hwa Shin Eunha Oh Yunjeong Kim Dae-Hwan Nam So Young Jeon Jin Hyuk Yu Dohsik Minn |
| author_sort | Min Hwa Shin |
| collection | DOAJ |
| description | Adoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in the treatment of hematological malignancies. However, their limitations in solid tumors include an immunosuppressive tumor microenvironment (TME), insufficient tumor infiltration, toxicity, and the absence of tumor-specific antigens. Although recent advances in CAR-T cell design—such as the incorporation of co-stimulatory domains and the development of armored CAR-T cells—have shown promising results in treating solid tumors, there are still challenges that need to be addressed. To overcome these limitations, other immune cells, such as natural killer (NK) cells and macrophages (M), have been developed as attractive options for efficient cancer immunotherapy of solid tumors. CAR-NK cells exhibit substantial clinical improvements with "off-the-shelf" availability and low toxicity. CAR-M cells have promising therapeutic potential because macrophages can infiltrate the TME of solid tumors. Here, we review the recent advances and future perspectives associated with engineered immune cell-based cancer immunotherapies for solid tumors. We also summarize ongoing clinical trials investigating the safety and efficacy of engineered immune cells, such as CAR-T, CAR-NK, and CAR-M, for targeting solid tumors. |
| first_indexed | 2024-03-11T02:39:10Z |
| format | Article |
| id | doaj.art-c3cacb824d144db393e868aa123e6566 |
| institution | Directory Open Access Journal |
| issn | 2073-4409 |
| language | English |
| last_indexed | 2024-03-11T02:39:10Z |
| publishDate | 2023-06-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Cells |
| spelling | doaj.art-c3cacb824d144db393e868aa123e65662023-11-18T09:43:20ZengMDPI AGCells2073-44092023-06-011212160610.3390/cells12121606Recent Advances in CAR-Based Solid Tumor ImmunotherapyMin Hwa Shin0Eunha Oh1Yunjeong Kim2Dae-Hwan Nam3So Young Jeon4Jin Hyuk Yu5Dohsik Minn6Immune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaImmune Research Institute, Seegene Medical Foundation, Seoul 04805, Republic of KoreaAdoptive cell therapy using chimeric antigen receptor (CAR) technology is one of the most advanced engineering platforms for cancer immunotherapy. CAR-T cells have shown remarkable efficacy in the treatment of hematological malignancies. However, their limitations in solid tumors include an immunosuppressive tumor microenvironment (TME), insufficient tumor infiltration, toxicity, and the absence of tumor-specific antigens. Although recent advances in CAR-T cell design—such as the incorporation of co-stimulatory domains and the development of armored CAR-T cells—have shown promising results in treating solid tumors, there are still challenges that need to be addressed. To overcome these limitations, other immune cells, such as natural killer (NK) cells and macrophages (M), have been developed as attractive options for efficient cancer immunotherapy of solid tumors. CAR-NK cells exhibit substantial clinical improvements with "off-the-shelf" availability and low toxicity. CAR-M cells have promising therapeutic potential because macrophages can infiltrate the TME of solid tumors. Here, we review the recent advances and future perspectives associated with engineered immune cell-based cancer immunotherapies for solid tumors. We also summarize ongoing clinical trials investigating the safety and efficacy of engineered immune cells, such as CAR-T, CAR-NK, and CAR-M, for targeting solid tumors.https://www.mdpi.com/2073-4409/12/12/1606CAR-TCAR-NKCAR-Mcancer immunotherapy |
| spellingShingle | Min Hwa Shin Eunha Oh Yunjeong Kim Dae-Hwan Nam So Young Jeon Jin Hyuk Yu Dohsik Minn Recent Advances in CAR-Based Solid Tumor Immunotherapy Cells CAR-T CAR-NK CAR-M cancer immunotherapy |
| title | Recent Advances in CAR-Based Solid Tumor Immunotherapy |
| title_full | Recent Advances in CAR-Based Solid Tumor Immunotherapy |
| title_fullStr | Recent Advances in CAR-Based Solid Tumor Immunotherapy |
| title_full_unstemmed | Recent Advances in CAR-Based Solid Tumor Immunotherapy |
| title_short | Recent Advances in CAR-Based Solid Tumor Immunotherapy |
| title_sort | recent advances in car based solid tumor immunotherapy |
| topic | CAR-T CAR-NK CAR-M cancer immunotherapy |
| url | https://www.mdpi.com/2073-4409/12/12/1606 |
| work_keys_str_mv | AT minhwashin recentadvancesincarbasedsolidtumorimmunotherapy AT eunhaoh recentadvancesincarbasedsolidtumorimmunotherapy AT yunjeongkim recentadvancesincarbasedsolidtumorimmunotherapy AT daehwannam recentadvancesincarbasedsolidtumorimmunotherapy AT soyoungjeon recentadvancesincarbasedsolidtumorimmunotherapy AT jinhyukyu recentadvancesincarbasedsolidtumorimmunotherapy AT dohsikminn recentadvancesincarbasedsolidtumorimmunotherapy |